Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.61 |
| ▸ | GSK3A | P49840 | 3/20 | 0.61 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095078 | 0.91 | GSK3B (0.74) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5094415 | 0.89 | GSK3B (0.57) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5093363 | 0.88 | GSK3B (0.62) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5100411 | 0.88 | GSK3B (0.55) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5094486 | 0.86 | GSK3B (0.63) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5099070 | 0.85 | GSK3B (0.64) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5094822 | 0.85 | GSK3B (0.62) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5099538 | 0.84 | GSK3B (0.62) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5089178 | 0.84 | GSK3B (0.62) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5100730 | 0.84 | GSK3B (0.76) | GSK3BGSK3ACDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | GSK3B 1/4885GSK3A 2/4885CDK1 7/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | GSK3B 1/4885GSK3A 2/4885CDK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.